drugset / Trial / NCT00620685

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

NCT00620685

Phase 2 Completed 27 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.

Timeline

Start
2008-03
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PH-797804 Small molecule 1 mg
Subject PH-797804 Small molecule 5 mg

Indications